These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35844991)

  • 1. Decitabine mildly attenuates
    Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
    EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
    [No Abstract]   [Full Text] [Related]  

  • 2. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
    Stumpel DJ; Schneider P; Pieters R; Stam RW
    Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan Induces Disease Remission in Xenograft Mouse Models of Pediatric
    Kerstjens M; Garrido Castro P; Pinhanços SS; Schneider P; Wander P; Pieters R; Stam RW
    Biomedicines; 2021 Jun; 9(7):. PubMed ID: 34201500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
    Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements.
    Roolf C; Richter A; Konkolefski C; Knuebel G; Sekora A; Krohn S; Stenzel J; Krause BJ; Vollmar B; Murua Escobar H; Junghanss C
    J Hematol Oncol; 2018 May; 11(1):62. PubMed ID: 29728108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
    Xiao L; Karsa M; Ronca E; Bongers A; Kosciolek A; El-Ayoubi A; Revalde JL; Seneviratne JA; Cheung BB; Cheung LC; Kotecha RS; Newbold A; Bjelosevic S; Arndt GM; Lock RB; Johnstone RW; Gudkov AV; Gurova KV; Haber M; Norris MD; Henderson MJ; Somers K
    Front Oncol; 2022; 12():863329. PubMed ID: 35677155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options.
    Stumpel DJ; Schneider P; van Roon EH; Boer JM; de Lorenzo P; Valsecchi MG; de Menezes RX; Pieters R; Stam RW
    Blood; 2009 Dec; 114(27):5490-8. PubMed ID: 19855078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
    Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia.
    Stam RW; den Boer ML; Passier MM; Janka-Schaub GE; Sallan SE; Armstrong SA; Pieters R
    Leukemia; 2006 Feb; 20(2):264-71. PubMed ID: 16357833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
    Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
    Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
    Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
    Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
    Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
    Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Stam RW; Den Boer ML; Schneider P; de Boer J; Hagelstein J; Valsecchi MG; de Lorenzo P; Sallan SE; Brady HJ; Armstrong SA; Pieters R
    Blood; 2010 Feb; 115(5):1018-25. PubMed ID: 19965632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells.
    Accordi B; Galla L; Milani G; Curtarello M; Serafin V; Lissandron V; Viola G; te Kronnie G; De Maria R; Petricoin EF; Liotta LA; Indraccolo S; Basso G
    Leukemia; 2013 Apr; 27(5):1019-27. PubMed ID: 23228943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PRMT1-mediated FLT3 methylation disrupts maintenance of MLL-rearranged acute lymphoblastic leukemia.
    Zhu Y; He X; Lin YC; Dong H; Zhang L; Chen X; Wang Z; Shen Y; Li M; Wang H; Sun J; Nguyen LX; Zhang H; Jiang W; Yang Y; Chen J; Müschen M; Chen CW; Konopleva MY; Sun W; Jin J; Carlesso N; Marcucci G; Luo Y; Li L
    Blood; 2019 Oct; 134(15):1257-1268. PubMed ID: 31395602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of Carfilzomib for Infant
    Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
    Front Oncol; 2021; 11():631594. PubMed ID: 33937032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
    Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
    Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.